It was a busy summer for Chinese pharmaceutical companies and investors who went global shopping, eying mega acquisition deals since China announced plans to accept overseas clinical trial data and global multicenter studies as part of its policies.

Sanofi signed a $2bn deal with DiCE Molecules to develop small molecules against targets previously addressed by biologics; Toshiba sold its diagnostics and medical imaging division to Canon for $6bn. Debt offerings dominated biopharma and device financings.